Equities Analysts Issue Forecasts for AGIO FY2027 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Agios Pharmaceuticals in a report issued on Thursday, March 6th. Zacks Research analyst A. Chakraborty expects that the biopharmaceutical company will earn ($3.85) per share for the year. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Several other equities research analysts also recently issued reports on AGIO. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Scotiabank increased their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target for the company. Royal Bank of Canada upped their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Trading Down 4.7 %

NASDAQ AGIO opened at $32.38 on Friday. The stock has a market cap of $1.86 billion, a P/E ratio of 2.86 and a beta of 0.88. The company’s fifty day simple moving average is $33.82 and its 200-day simple moving average is $42.42. Agios Pharmaceuticals has a 52 week low of $27.14 and a 52 week high of $62.58.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Erste Asset Management GmbH purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at $97,199,000. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $49,290,000. Vestal Point Capital LP purchased a new position in Agios Pharmaceuticals in the third quarter valued at about $33,767,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $9,957,000. Finally, Paradigm Biocapital Advisors LP acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth $9,084,000.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.